logo

Celldex Therapeutics Inc. (CLDX)



Trade CLDX now with
  Date
  Headline
3/29/2021 6:40:35 AM Celldex Reports 80% CR Rate In Interim Data Update From Phase 1b Study Of CDX-0159 In Chronic Inducible Urticaria
1/4/2021 8:22:39 AM Celldex Appoints Freddy Jimenez SVP And General Counsel
10/13/2020 8:16:51 AM Celldex Says First Patient Dosed In Randomized, Double-blind Phase 1b Study Of CDX-0159
5/6/2020 8:07:07 AM Celldex Says Results From Phase 1 Study Of CDX-0159 Accepted As Late-breaking Poster Presentation At EAACI
11/8/2016 12:07:02 PM Wedbush Is Increasing Celldex Therapeutics Inc. (CLDX) 2016 Rev. Estimate To 5.16 M From 3.19 M
11/8/2016 12:06:27 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) 2017 Estimate To -0.91 From -1.13
11/8/2016 12:06:02 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) Q4 17 Estimate To -0.20 From -0.24
11/8/2016 12:05:49 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) Q3 17 Estimate To -0.20 From -0.24
11/8/2016 12:05:34 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) Q2 17 Estimate To -0.27 From -0.35
11/8/2016 12:05:18 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) Q1 17 Estimate To -0.27 From -0.34
11/8/2016 12:04:57 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) 2016 Estimate To -1.22 From -1.34
11/8/2016 12:04:32 PM Wedbush Is Raising Celldex Therapeutics Inc. (CLDX) Q4 16 Estimate To -0.26 From -0.34
11/8/2016 12:04:04 PM Wedbush Reiterates Celldex Therapeutics Inc. (CLDX) At Neutral With $3 Price Target